Lyell is a clinical-stage cell therapy company dedicated to advancing next-generation CAR T-cell product candidates for patients with hematologic malignancies and solid tumors. The company pioneers novel approaches designed to generate T cells with potent cancer cell killing capabilities that drive long-lasting clinical responses, leveraging proprietary ex vivo genetic (Gen-R) and epigenetic (Epi-R) reprogramming technology platforms.
Lyell is publicly traded
IPO'd on June 17, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under LYEL.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Employees
220–300
Total Funding
$834M
3 rounds
Total raised $834M across 3 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series C
Date
March 2020
Amount
$493M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| March 2020 | Series C | $493M | — | Not disclosed |
| 2019 | Series A | $179M | — | ARCH Venture Partners |
| 2019 | Series B | $162M | — | Not disclosed |
Lynn Seely, M.D.
President and Chief Executive Officer
Rick Klausner, M.D.
Founder & Chairman of the Board
Crystal Mackall, M.D.
Founder
Stan Riddell, M.D.
Founder
Gary Lee, Ph.D.
Chief Scientific Officer
Stephen Hill, M.B.A.
Chief Operating Officer
David Shook, M.D.
Chief Medical Officer
Smital Shah
Chief Financial and Business Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Juno Therapeutics
Developer of CAR-T cell therapies for hematologic malignancies; acquired by Bristol-Myers Squibb.
Kite Pharma
Commercial leader in CAR-T therapies for lymphoma and leukemia; acquired by Gilead Sciences.
Orca Bio
Cell therapy company developing allogeneic CAR-T treatments; partnership with Lyell for solid tumors.
Achilles Therapeutics
Cell therapy company developing personalized T-cell therapies for cancer.
Yes, Lyell is publicly traded under the ticker symbol LYEL on the NASDAQ. The company went public in June 17, 2021.
Lyell trades under the ticker symbol LYEL on the NASDAQ. It began trading in June 17, 2021.
Lyell (LYEL on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker LYEL to place an order.
Lyell went public in June 17, 2021 via ipo. Lyell Immunopharma went public on NASDAQ under ticker LYEL on June 17, 2021, raising $425 million in its IPO at $17.00 per share. The company is the third largest biotech IPO in history.
Lyell raised $834M across 3 disclosed funding rounds prior to its public listing.
Lyell was co-founded by Rick Klausner, M.D., Crystal Mackall, M.D., and Stan Riddell, M.D. in 2018.
Lyell is headquartered in South San Francisco, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.